File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Therapeutic potential of angiotensin receptor blockers in hypertension

TitleTherapeutic potential of angiotensin receptor blockers in hypertension
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2006
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eid
Citation
Expert Opinion On Investigational Drugs, 2006, v. 15 n. 6, p. 625-635 How to Cite?
AbstractThe renin-angiotensin-aldosterone system plays a key role in the regulation of fluid and electrolyte balance. Angiotensin II receptor blockers (ARBs) inhibit angiotensin II type 1 receptors and large clinical trials have shown that they are effective in many cardiovascular diseases including hypertension, heart failure, myocardial infarction and diabetic nephropathy. They lower blood pressure effectively, are very well tolerated and can be used as monotherapy or in combination with other drug classes for the treatment of hypertension. ARBs are particularly suitable for hypertensive patients with co-morbities such as diabetes, microalbuminuria, proteinuria, left ventricular hypertrophy and heart failure. Unlike angiotensin-converting enzyme inhibitors, ARBs do not cause persistent dry cough. For patients in whom angiotensin-converting enzyme inhibitors are indicated but not tolerated, an ARB should be considered. Periodic monitoring of renal function and electrolytes is required in patients treated with an ARB. © 2006 Informa UK Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/91496
ISSN
2015 Impact Factor: 4.408
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMYen_HK
dc.date.accessioned2010-09-17T10:20:21Z-
dc.date.available2010-09-17T10:20:21Z-
dc.date.issued2006en_HK
dc.identifier.citationExpert Opinion On Investigational Drugs, 2006, v. 15 n. 6, p. 625-635en_HK
dc.identifier.issn1354-3784en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91496-
dc.description.abstractThe renin-angiotensin-aldosterone system plays a key role in the regulation of fluid and electrolyte balance. Angiotensin II receptor blockers (ARBs) inhibit angiotensin II type 1 receptors and large clinical trials have shown that they are effective in many cardiovascular diseases including hypertension, heart failure, myocardial infarction and diabetic nephropathy. They lower blood pressure effectively, are very well tolerated and can be used as monotherapy or in combination with other drug classes for the treatment of hypertension. ARBs are particularly suitable for hypertensive patients with co-morbities such as diabetes, microalbuminuria, proteinuria, left ventricular hypertrophy and heart failure. Unlike angiotensin-converting enzyme inhibitors, ARBs do not cause persistent dry cough. For patients in whom angiotensin-converting enzyme inhibitors are indicated but not tolerated, an ARB should be considered. Periodic monitoring of renal function and electrolytes is required in patients treated with an ARB. © 2006 Informa UK Ltd.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eiden_HK
dc.relation.ispartofExpert Opinion on Investigational Drugsen_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAngiotensin II Type 1 Receptor Blockers - administration & dosage - therapeutic useen_HK
dc.subject.meshBenzimidazoles - administration & dosage - therapeutic useen_HK
dc.subject.meshBlood Pressure - drug effectsen_HK
dc.subject.meshCoronary Disease - drug therapy - mortality - physiopathologyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHypertension - drug therapy - mortality - physiopathologyen_HK
dc.subject.meshLosartan - administration & dosage - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMeta-Analysis as Topicen_HK
dc.subject.meshMyocardial Infarction - drug therapy - mortality - physiopathologyen_HK
dc.subject.meshPractice Guidelines as Topicen_HK
dc.subject.meshRandomized Controlled Trials as Topicen_HK
dc.subject.meshRenin-Angiotensin System - drug effectsen_HK
dc.subject.meshSurvival Analysisen_HK
dc.subject.meshTetrazoles - administration & dosage - therapeutic useen_HK
dc.subject.meshValine - administration & dosage - analogs & derivatives - therapeutic useen_HK
dc.titleTherapeutic potential of angiotensin receptor blockers in hypertensionen_HK
dc.typeArticleen_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/13543784.15.6.625en_HK
dc.identifier.pmid16732715en_HK
dc.identifier.scopuseid_2-s2.0-33745233054en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33745233054&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue6en_HK
dc.identifier.spage625en_HK
dc.identifier.epage635en_HK
dc.identifier.isiWOS:000238376600004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.citeulike683199-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats